Literature DB >> 22509960

Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone.

Raul López-Arnau1, Jose Martínez-Clemente, David Pubill, Elena Escubedo, Jorge Camarasa.   

Abstract

BACKGROUND AND
PURPOSE: Here, we have compared the neurochemical profile of three new cathinones, butylone, mephedrone and methylone, in terms of their potential to inhibit plasmalemmal and vesicular monoamine transporters. Their interaction with 5-HT and dopamine receptors and their psychostimulant effect was also studied. EXPERIMENTAL APPROACH: Locomotor activity was recorded in mice following different doses of cathinones. Monoamine uptake assays were performed in purified rat synaptosomes. Radioligand-binding assays were carried out to assess the affinity of these compounds for monoamine transporters or receptors. KEY
RESULTS: Butylone, mephedrone and methylone (5-25 mg·kg(-1) ) caused hyperlocomotion, which was prevented with ketanserin or haloperidol. Methylone was the most potent compound inhibiting both [(3) H]5-HT and [(3) H]dopamine uptake with IC(50) values that correlate with its affinity for dopamine and 5-HT transporter. Mephedrone was found to be the cathinone derivative with highest affinity for vesicular monoamine transporter-2 causing the inhibition of dopamine uptake. The affinity of cathinones for 5-HT(2A) receptors was similar to that of MDMA. CONCLUSIONS AND IMPLICATIONS: Butylone and methylone induced hyperlocomotion through activating 5-HT(2A) receptors and increasing extra-cellular dopamine. They inhibited 5-HT and dopamine uptake by competing with substrate. Methylone was the most potent 5-HT and dopamine uptake inhibitor and its effect partly persisted after withdrawal. Mephedrone-induced hyperlocomotion was dependent on endogenous 5-HT. Vesicular content played a key role in the effect of mephedrone, especially for 5-HT uptake inhibition. The potency of mephedrone in inhibiting noradrenaline uptake suggests a sympathetic effect of this cathinone.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22509960      PMCID: PMC3481047          DOI: 10.1111/j.1476-5381.2012.01998.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

Authors:  J C McGrath; G B Drummond; E M McLachlan; C Kilkenny; C L Wainwright
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Drugs for youth via Internet and the example of mephedrone.

Authors:  I Vardakou; C Pistos; Ch Spiliopoulou
Journal:  Toxicol Lett       Date:  2010-12-25       Impact factor: 4.372

3.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

4.  Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply.

Authors:  Karen McElrath; Christina O'Neill
Journal:  Int J Drug Policy       Date:  2011-01-15

5.  In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.

Authors:  David Erritzoe; Vibe G Frokjaer; Klaus K Holst; Maria Christoffersen; Sys S Johansen; Claus Svarer; Jacob Madsen; Peter M Rasmussen; Thomas Ramsøy; Terry L Jernigan; Gitte M Knudsen
Journal:  Arch Gen Psychiatry       Date:  2011-06

6.  Cytochrome P450 is regulated by noradrenergic and serotonergic systems.

Authors:  Marta Kot; Władysława A Daniel
Journal:  Pharmacol Res       Date:  2011-06-30       Impact factor: 7.658

7.  Mephedrone: use, subjective effects and health risks.

Authors:  Adam Winstock; Luke Mitcheson; John Ramsey; Susannah Davies; Malgorzata Puchnarewicz; John Marsden
Journal:  Addiction       Date:  2011-07-27       Impact factor: 6.526

Review 8.  Regulation of monoamine transporters: Role of transporter phosphorylation.

Authors:  Sammanda Ramamoorthy; Toni S Shippenberg; Lankupalle D Jayanthi
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

9.  The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice.

Authors:  Jorge Camarasa; Sara García Ratés; David Pubill; Elena Escubedo
Journal:  Behav Pharmacol       Date:  2009-10       Impact factor: 2.293

Review 10.  Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.

Authors:  Fabrizio Schifano; Antonio Albanese; Suzanne Fergus; Jackie L Stair; Paolo Deluca; Ornella Corazza; Zoe Davey; John Corkery; Holger Siemann; Norbert Scherbaum; Magi' Farre'; Marta Torrens; Zsolt Demetrovics; A Hamid Ghodse
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

View more
  68 in total

1.  Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.

Authors:  Amy J Eshleman; Shanthi Nagarajan; Katherine M Wolfrum; John F Reed; Tracy L Swanson; Aaron Nilsen; Aaron Janowsky
Journal:  Psychopharmacology (Berl)       Date:  2018-11-05       Impact factor: 4.530

2.  Reinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats.

Authors:  Charles W Schindler; Eric B Thorndike; Steven R Goldberg; Kurt R Lehner; Nicholas V Cozzi; Simon D Brandt; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2015-08-29       Impact factor: 4.530

3.  Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones.

Authors:  Michael B Gatch; Cynthia M Taylor; Michael J Forster
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

Review 4.  Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

Authors:  Christopher L German; Annette E Fleckenstein; Glen R Hanson
Journal:  Life Sci       Date:  2013-08-02       Impact factor: 5.037

Review 5.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

6.  Investigation of "bath salts" use patterns within an online sample of users in the United States.

Authors:  Patrick S Johnson; Matthew W Johnson
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

7.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

Review 8.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 9.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

10.  Stereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates.

Authors:  Alexandre Vouga; Ryan A Gregg; Maryah Haidery; Anita Ramnath; Hassan K Al-Hassani; Christopher S Tallarida; David Grizzanti; Robert B Raffa; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Neuropharmacology       Date:  2014-12-09       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.